Abstract
Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today's society.
Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.
Keywords: Gene therapy, Neurodegenerative disorder, Antisense oligonucleotide, Clinical trial, Viral vectors, Central nervous system.
Current Gene Therapy
Title:Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders
Volume: 17 Issue: 3
Author(s): Aneesh Donde, Philip C. Wong and Liam L. Chen*
Affiliation:
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205,United States
Keywords: Gene therapy, Neurodegenerative disorder, Antisense oligonucleotide, Clinical trial, Viral vectors, Central nervous system.
Abstract: Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today's society.
Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.
Export Options
About this article
Cite this article as:
Donde Aneesh , Wong C. Philip and Chen L. Liam *, Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders, Current Gene Therapy 2017; 17 (3) . https://dx.doi.org/10.2174/1566523217666171013124150
DOI https://dx.doi.org/10.2174/1566523217666171013124150 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Synaptic Dysfunction in Synucleinopathies
CNS & Neurological Disorders - Drug Targets Protein Conformational Misfolding and Amyloid Formation: Characteristics of a New Class of Disorders that Include Alzheimers and Prion Diseases
Current Medicinal Chemistry Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Patent Selections
Recent Patents on Biomarkers Smart Biodegradable Nanoparticulate Materials: Poly-lactide-co-glycolide Functionalization with Selected Peptides
Current Nanoscience Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Biological Activity of Some Volatile Diterpenoids
Current Bioactive Compounds Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The “LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD
Current Alzheimer Research Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories
Current Neuropharmacology Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine